Related Experiment Video
Updated: Jul 19, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
AIDS oncology
1Johns Hopkins Oncology Center, Baltimore, Maryland 21231, USA.
Current Opinion in Infectious Diseases
|October 13, 2006
Summary
New diagnostic methods may avoid brain biopsies for primary central nervous system lymphoma. Advances include reduced-dose chemotherapy for non-Hodgkin
Area of Science:
- Oncology
- Hematology
- Immunology
Background:
- Primary central nervous system lymphoma (PCNSL) diagnosis often requires invasive brain biopsy.
- Non-Hodgkin's lymphoma (NHL) treatment protocols are evolving.
- Kaposi's sarcoma (KS) and Epstein-Barr virus (EBV)-associated lymphomas present ongoing therapeutic challenges.
Purpose of the Study:
- To review recent advancements in the diagnosis and treatment of various lymphomas and related conditions.
- To highlight non-invasive diagnostic strategies for PCNSL.
- To discuss novel therapeutic agents and approaches for hematologic malignancies and viral-associated B-cell lymphomas.
Main Methods:
- Review of recent literature on diagnostic techniques for PCNSL.
- Analysis of randomized controlled trials for reduced-dose chemotherapy in NHL.
- Summary of emerging treatments for Kaposi's sarcoma.
- Evaluation of adoptive cellular immunotherapy for EBV-associated B-cell lymphomas.
Main Results:
- Novel diagnostic approaches may obviate the need for brain biopsy in many PCNSL cases.
- Reduced-dose chemotherapy demonstrated advantages in a randomized controlled trial for NHL.
- New therapeutic agents are available for Kaposi's sarcoma treatment.
- Adoptive cellular immunotherapy shows efficacy in preventing and treating EBV-associated B-cell lymphomas post-bone marrow transplant.
Conclusions:
- Diagnostic strategies for PCNSL are improving, potentially reducing invasive procedures.
- Chemotherapy regimens for NHL are being refined for better outcomes.
- Therapeutic options for Kaposi's sarcoma have expanded.
- Cellular immunotherapy holds promise for managing specific B-cell lymphomas, particularly in immunocompromised patients.
Related Concept Videos
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:18Cancer
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...